Finding hope during COVID-19
As people were dying of COVID-19 and no vaccine yet existed, a global pharmaceutical company quickly developed a novel monoclonal antibody (mAb) treatment. With emergency use authorization from the FDA, they needed to disseminate trustworthy information to healthcare providers and the general population, particularly those at high risk for severe COVID-19, as well as healthcare providers.
The pharmaceutical company tapped TrendyMinds to help them urgently organize, design, and launch an awareness strategy and materials. They required detailed playbooks for healthcare providers and infusion centers, as well as materials to reach potential patients and state and federal governments to raise awareness of the treatments.
In six months, the campaign garnered more than two billion impressions, and drove millions of visitors to CombatCovid.HHS.gov. Hundreds of thousands of users clicked to find mAb treatments near them. More than 500,000 patients in 20 countries received infusions of this mAb treatment, vastly reducing their risk of severe illness, hospitalization, or death.
FinalistFierce Pharma Award-Nominated